TMO

Over the past six months (November 2025 - May 2026), Thermo Fisher Scientific's stock (TMO) has experienced several notable events and trends. The stock was trading at $579.42 at the beginning of 2026 and has since decreased by 19.8% to $464.6370 as of early May 2026. The company reported strong fourth-quarter 2025 results, with revenue and earnings exceeding expectations. Thermo Fisher Scientific increased its quarterly dividend from $0.43 to $0.47 per share, which was paid on April 15, 2026. The company reported Q1 2026 results that beat top- and bottom-line estimates, with adjusted EPS of $5.44 and revenue of $11.01 billion. Thermo Fisher Scientific announced an agreement to sell its microbiology business to Astorg for approximately $1.075 billion. The stock performance has been influenced by broader macroeconomic and life sciences industry headwinds, including cautious spending from biotech customers and the normalization of post-pandemic activity. The company's increased debt load following the Clario acquisition has also been cited as a factor impacting the stock. Significant insider selling has also been noted as a factor affecting the stock.